218 related articles for article (PubMed ID: 34928497)
21. Five-alpha reductase inhibitors and risk of prostate cancer among men with benign prostatic hyperplasia: A historical cohort study using primary care data.
Thakrar DB; Douglas IJ; Smeeth L; Bhaskaran K
Wellcome Open Res; 2023; 8():295. PubMed ID: 38774490
[No Abstract] [Full Text] [Related]
22. The therapeutic effects of Stauntonia hexaphylla in benign prostate hyperplasia are mediated by the regulation of androgen receptors and 5α-reductase type 2.
Hong GL; Park SR; Jung DY; Karunasagara S; Lee KP; Koh EJ; Cho K; Park SS; Jung JY
J Ethnopharmacol; 2020 Mar; 250():112446. PubMed ID: 31812646
[TBL] [Abstract][Full Text] [Related]
23. Ageratum conyzoides L. inhibits 5-alpha-reductase gene expression in human prostate cells and reduces symptoms of benign prostatic hypertrophy in otherwise healthy men in a double blind randomized placebo controlled clinical study.
Detering M; Steels E; Koyyalamudi SR; Allifranchini E; Bocchietto E; Vitetta L
Biofactors; 2017 Nov; 43(6):789-800. PubMed ID: 29048765
[TBL] [Abstract][Full Text] [Related]
24. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
Habib FK; Ross M; Tate R; Chisholm GD
Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
[TBL] [Abstract][Full Text] [Related]
25. The Use of 5-Alpha Reductase Inhibitors to Manage Benign Prostatic Hyperplasia and the Risk of All-cause Mortality.
Wallner LP; DiBello JR; Li BH; Van Den Eeden SK; Weinmann S; Ritzwoller DP; Abell JE; D'Agostino R; Loo RK; Aaronson DS; Horwitz RI; Jacobsen SJ
Urology; 2018 Sep; 119():70-78. PubMed ID: 29906480
[TBL] [Abstract][Full Text] [Related]
26. 5α-Reductase Inhibitors (5ARIs) and Male Reproduction.
Drobnis EZ; Nangia AK
Adv Exp Med Biol; 2017; 1034():59-61. PubMed ID: 29256127
[TBL] [Abstract][Full Text] [Related]
27. SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists.
Gu X; Na R; Huang T; Wang L; Tao S; Tian L; Chen Z; Jiao Y; Kang J; Zheng S; Xu J; Sun J; Qi J
J Urol; 2013 Aug; 190(2):615-9. PubMed ID: 23499746
[TBL] [Abstract][Full Text] [Related]
28. Selective estrogen receptor modulators regulate stromal proliferation in human benign prostatic hyperplasia by multiple beneficial mechanisms--action of two new agents.
Kumar R; Verma V; Sarswat A; Maikhuri JP; Jain A; Jain RK; Sharma VL; Dalela D; Gupta G
Invest New Drugs; 2012 Apr; 30(2):582-93. PubMed ID: 21181231
[TBL] [Abstract][Full Text] [Related]
29. Risk Analysis of Prostate Cancer Development Following Five-alpha Reductase Inhibitor Treatment for Benign Prostate Hyperplasia.
Chang LW; Wang SS; Yang CK; Lu K; Chen CS; Cheng CL; Hung SC; Chiu KY; Hsu CY; Li JR
Anticancer Res; 2023 Jan; 43(1):485-491. PubMed ID: 36585197
[TBL] [Abstract][Full Text] [Related]
30. Club-like cells in proliferative inflammatory atrophy of the prostate.
Huang FW; Song H; Weinstein HN; Xie J; Cooperberg MR; Hicks J; Mummert L; De Marzo AM; Sfanos KS
J Pathol; 2023 Sep; 261(1):85-95. PubMed ID: 37550827
[TBL] [Abstract][Full Text] [Related]
31. Cynanchum wilfordii Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia by Regulating 5α-Reductase and Androgen Receptor Activities in a Rat Model.
Lee G; Shin J; Choi H; Jo A; Pan S; Bae D; Lee Y; Choi C
Nutrients; 2017 Sep; 9(10):. PubMed ID: 28953224
[TBL] [Abstract][Full Text] [Related]
32. Five-alpha reductase inhibitor influences expression of androgen receptor and HOXB13 in human hyperplastic prostate tissue.
Jung C; Park Y; Kim YR; Ryu SB; Kang TW
Int Braz J Urol; 2013; 39(6):875-83. PubMed ID: 24456780
[TBL] [Abstract][Full Text] [Related]
33. PSA density is associated with BPH cellular composition.
Jia L; Strand DW; Goueli RS; Gahan JC; Roehrborn CG; Mauck RJ
Prostate; 2022 Sep; 82(12):1162-1169. PubMed ID: 35652548
[TBL] [Abstract][Full Text] [Related]
34. Drug Insight: 5alpha-reductase inhibitors for the treatment of benign prostatic hyperplasia.
Marberger M
Nat Clin Pract Urol; 2006 Sep; 3(9):495-503. PubMed ID: 16964191
[TBL] [Abstract][Full Text] [Related]
35. MRI characterization of the dynamic effects of 5α-reductase inhibitors on prostate zonal volumes.
Truong H; Logan J; Turkbey B; Siddiqui MM; Rais-Bahrami S; Hoang AN; Pusateri C; Shuch B; Walton-Diaz A; Vourganti S; Nix J; Stamatakis L; Harris C; Chua C; Choyke PL; Wood BJ; Pinto PA
Can J Urol; 2013 Dec; 20(6):7002-7. PubMed ID: 24331340
[TBL] [Abstract][Full Text] [Related]
36. [Pharmacological treatment of benign prostatic hyperplasia].
Oelke M; Martinelli E
Urologe A; 2016 Jan; 55(1):81-94; quiz 95-6. PubMed ID: 26676726
[TBL] [Abstract][Full Text] [Related]
37. Impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality.
Van Rompay MI; Curtis Nickel J; Ranganathan G; Kantoff PW; Solomon KR; Lund JL; McKinlay JB
BJU Int; 2019 Mar; 123(3):511-518. PubMed ID: 30216624
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the effects of new specific azasteroid inhibitors of steroid 5 alpha-reductase on canine hyperplastic prostate: suppression of prostatic DHT correlated with prostate regression.
Cohen SM; Werrmann JG; Rasmusson GH; Tanaka WK; Malatesta PF; Prahalada S; Jacobs JG; Harris G; Nett TM
Prostate; 1995 Feb; 26(2):55-71. PubMed ID: 7531846
[TBL] [Abstract][Full Text] [Related]
39. A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.
Montorsi F; Alcaraz A; Desgrandchamps F; Hammerer P; Schröder F; Castro R
Prostate; 2009 Jun; 69(8):895-907. PubMed ID: 19267353
[TBL] [Abstract][Full Text] [Related]
40. Combination therapies for improved management of lower urinary tract symptoms/benign prostatic hyperplasia.
De Nunzio C; Presicce F; Tubaro A
Drugs Today (Barc); 2016 Sep; 52(9):501-517. PubMed ID: 27883117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
